|Bid||63.80 x 900|
|Ask||65.43 x 1400|
|Day's Range||63.92 - 66.64|
|52 Week Range||32.95 - 90.19|
|Beta (5Y Monthly)||1.18|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Shareholders in Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) had a terrible week, as shares crashed 23% to US$67.10 in...
Shares of Arena Pharmaceuticals (NASDAQ: ARNA) are plummeting today, down by 22% as of 1:35 p.m. EST, after the biotech released data from a mid-stage study of etrasimod in patients with atopic dermatitis, commonly called eczema. The good news is that there are some hints that etrasimod might be helping patients with eczema. Using that measurement, there wasn't a statistical difference between either of the two dose levels of etrasimod compared to a placebo after 12 weeks of treatment.
Arena Pharmaceuticals (ARNA) beats bottom-line estimates for third-quarter 2020. Mid-stage atopic dermatitis study on etrasimod fails to meet primary endpoint but phase III study may start soon.